Neuphoria Therapeutics Inc. (NEUP)
NASDAQ: NEUP · Real-Time Price · USD
2.350
+0.030 (1.29%)
Nov 20, 2026, 4:00 PM EST - Market closed
Neuphoria Therapeutics Revenue
Neuphoria Therapeutics had revenue of $1.17M in the twelve months ending September 30, 2026, down -92.50% year-over-year. In the fiscal year ending June 30, 2026, Neuphoria Therapeutics had annual revenue of $1.17M, down -92.50%. That makes Neuphoria Therapeutics the 43,372nd largest company in the world by revenue and 6,028th in the United States.
Revenue (ttm)
$1.17M
Revenue Growth
-92.50%
P/S Ratio
10.83
Revenue / Employee
$1,174,165
Employees
1
Market Cap
12.72M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2026 | 1.17M | -14.48M | -92.50% |
| Jun 30, 2025 | 15.65M | - | - |
| Jun 30, 2024 | - | - | - |
| Jun 30, 2023 | - | - | - |
| Jun 30, 2022 | 4.17M | 3.48M | 499.60% |
| Jun 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| BioStem Technologies | 31.75M |
| Bolt Biotherapeutics | 4.70M |
| Seres Therapeutics | 2.13M |
| BeyondSpring | 1.88M |
| Pluri | 1.46M |
| Allarity Therapeutics | 350.00K |
| BioCardia | 3.00K |
NEUP News
- 6 days ago - Neuphoria Therapeutics Quarterly report: Q1 2027 - Filings
- 2 months ago - Neuphoria Therapeutics Proxy statement: Proxy filing - Filings
- 2 months ago - Neuphoria Therapeutics Proxy statement: Proxy filing - Filings
- 2 months ago - Neuphoria Therapeutics Proxy statement: Proxy filing - Filings
- 2 months ago - Neuphoria Therapeutics Annual report: Q4 2026 - Filings
- 4 months ago - Neuphoria Therapeutics Proxy statement: Proxy filing - Filings
- 4 months ago - Neuphoria Therapeutics to be acquired by Scancell - TheFly
- 4 months ago - Scancell and Neuphoria Therapeutics Announce Merger Agreement and Financing - GlobeNewsWire